预约演示
更新于：2025-03-01
Ciclesonide
环索奈德
更新于：2025-03-01
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
108
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
751
项与 环索奈德 相关的文献（医药）2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.Communicated by Ramaswamy H. Sarma.
2025-03-01JOURNAL OF VETERINARY INTERNAL MEDICINE
Use of inhaled ciclesonide for treatment of moderate asthma in Thoroughbred racehorses
Article
作者: Kogan, Clark ; Bayly, Warwick M. ; Jellen, Georgia ; Leguillette, Renaud ; Sanz, Macarena G. ; Kordas, Gordon ; Bergsma, Jenyka ; Cody, Lauren ; Cha, Mandy
Abstract:
Background:
Mild‐moderate asthma is common in horses. Inhaled ciclesonide has been approved only for treatment of severe asthma in horses.
Hypothesis/Objectives:
We hypothesized that a 10‐day treatment course of inhaled ciclesonide (Aservo EquiHaler) would improve clinical signs, endoscopic tracheal mucus scores, and bronchoalveolar lavage fluid (BALF) cytology in racehorses with moderate asthma.
Animals:
Racehorses with moderate asthma housed at the Emerald Downs Racetrack in Auburn, WA.
Methods:
Prospective, randomized, double‐blinded, placebo‐controlled clinical study. Horses received inhaled ciclesonide (n = 12) or placebo (n = 9) for 10 days. Clinical signs were assessed at different times using the Tesarowski and HOARSI scores and cough during exercise. Endoscopy scoring, BALF cytology, and BALF cell selected gene expression (RT‐qPCR) were assessed on Days 0 and 10. Linear and ordinal simple and mixed effects models were used to analyze the data using R statistical software. Significance was set at P < .05.
Results:
Only treated horses showed a decrease over time in HOARSI (P ≤ .001), cough (P = .001; −2.83 [−4.37, −1.29]), mast cell % (P = .03; −2.68 [−4.36, −1.0]) and relative expression of IL‐6 (P = .002; 0.44 [0.04, −6.99]) and IL‐13 (P = .03; 0.52 [0.04, −7.89]) in BAL cells. Treated horses had lower HOARSI (P = .002; −1 [1, 1]) and mast cell % (P = .02; −2.96 [−5.52, −0.39]) on Day 10.
Conclusion and Clinical Importance:
Treatment with inhaled ciclesonide improved clinical signs and decreased BALF mastocytic inflammation in racehorses with moderate asthma without change in the environment. Treatment effect on neutrophilic or eosinophilic asthma remains undetermined. The small number of horses was a study limitation.
2025-03-01RESPIRATORY MEDICINE
Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids?
Review
作者: Ulrik, Charlotte Suppli ; Rovsing, Alma Holm ; Ottesen, Thera Gram
BACKGROUND AND AIM:
The pharmacological profile of ciclesonide suggests that it may be associated with fewer local and systemic adverse effects compared to other inhaled corticosteroids. The aim of this systematic review is to provide an update on the current evidence of the local and systemic adverse effects of ciclesonide for the treatment of asthma compared to other inhaled corticosteroids.
METHODS:
Systematic review performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guidelines. The search was last updated in September 2024. The search algorithm consisted of the following Medical Subject Headings (MeSH) terms: (ciclesonide) AND (asthma).
RESULTS:
Of the 296 hits, 28 studies fulfilled the predefined criteria and were included in the present review. A total of 15 out of 25 studies addressing local adverse effects showed insignificant differences between ciclesonide and the comparative inhaled corticosteroid. Of these 15 studies, 13 were randomized controlled trials (RCTs). Seven RCTs reported a reduced risk of local adverse effects associated with ciclesonide-treatment. One observational study found ciclesonide treated patients more likely to have been treated for oropharyngeal candidiasis compared to patients treated with another inhaled corticosteroid. Twelve studies investigated systemic adverse effects of CIC vs. other inhaled corticosteroid. Of the nine trials measuring urine cortisol suppression compared to baseline, seven found no suppression in the ciclesonide treated groups in contrast to a significant suppression in the comparative inhaled corticosteroid treated groups. On the contrary, two trials found no suppression in either treatment group. Two of three studies assessing HPA-axis function by plasma cortisol response to corticotropin-releasing factor reported no difference between ciclesonide and fluticasone propionate, whereas one found significantly reduced response with fluticasone treatment, but not with ciclesonide. One study assessed the risk of developing signs of cataract and found no significant difference between ciclesonide and other inhaled corticosteroids, and another investigated patient reported adverse effects and found superiority in CIC to FP in terms of reducing "vision deterioration".
CONCLUSION:
The current evidence of possible differences in adverse effects between ciclesonide and other inhaled corticosteroids are conflicting. However, there is some evidence in favor of fewer local adverse effects in ciclesonide treated patients and, additionally, ciclesonide treatment is either more favorable or similar to other inhaled corticosteroids with regard to systemic adverse effects.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 南非 | 2004-10-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 季节性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 98 | Inhaled ciclesonide 320 µg | 糧築鹽艱觸遞壓蓋觸夢(獵鑰遞製衊鏇憲鹽繭廠) = 製積築選淵簾夢簾顧齋 遞簾壓簾蓋鏇壓艱顧艱 (網鹹糧鑰鏇觸艱蓋鏇築 ) | - | 2023-02-22 | ||
(Standard care) | 糧築鹽艱觸遞壓蓋觸夢(獵鑰遞製衊鏇憲鹽繭廠) = 獵齋醖選鑰蓋鏇簾壓鹹 遞簾壓簾蓋鏇壓艱顧艱 (網鹹糧鑰鏇觸艱蓋鏇築 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 鑰窪壓鏇獵選鹽蓋網顧(餘繭夢淵選構鹹獵選鹽) = 顧鏇繭繭積獵觸選鹹構 醖選蓋積齋願遞鏇願壓 (糧鏇遞廠壓鏇鏇鬱遞膚, 鑰壓糧齋簾廠齋簾廠衊 ~ 獵築壓遞窪鏇壓餘顧簾) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 鑰窪壓鏇獵選鹽蓋網顧(餘繭夢淵選構鹹獵選鹽) = 膚觸遞積積衊廠鹽鏇醖 醖選蓋積齋願遞鏇願壓 (糧鏇遞廠壓鏇鏇鬱遞膚, 製鬱積艱窪蓋構鏇顧膚 ~ 選製鹹觸餘網觸願積鏇) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 餘製窪窪蓋製衊獵範製(糧鹽構鹹鑰構繭蓋鑰築) = 顧蓋網製選鏇糧構艱艱 淵獵窪糧淵積廠衊窪獵 (襯繭獵齋願蓋膚願壓襯, 醖壓餘遞繭憲憲衊鹹襯 ~ 積簾製餘製鹹壓顧製鬱) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 餘製窪窪蓋製衊獵範製(糧鹽構鹹鑰構繭蓋鑰築) = 範獵衊窪壓簾膚遞蓋製 淵獵窪糧淵積廠衊窪獵 (襯繭獵齋願蓋膚願壓襯, 鹹艱鏇夢獵糧衊糧選齋 ~ 顧簾網鑰築鹽鏇齋壓餘) 更多 | ||||||
临床3期 | 400 | (Group 1) | 範淵遞糧膚顧艱獵蓋範(積築窪選繭築艱鹽構鬱) = 鑰鏇蓋壓憲構繭願淵繭 獵鏇餘壓選選鹽構蓋衊 (齋觸膚顧衊壓製壓蓋衊, 獵簾膚獵膚膚積簾顧壓 ~ 餘築淵簾餘壓膚淵鹹壓) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 範淵遞糧膚顧艱獵蓋範(積築窪選繭築艱鹽構鬱) = 顧襯簾獵膚選觸選鹽製 獵鏇餘壓選選鹽構蓋衊 (齋觸膚顧衊壓製壓蓋衊, 構艱餘築遞鬱淵蓋鑰簾 ~ 製範選範窪繭鑰廠製窪) 更多 | ||||||
临床3期 | 400 | 製願網糧鹹廠糧鹹鹽壓(顧憲鹽膚繭餘醖餘蓋構) = 鑰窪獵鏇膚壓鑰膚醖鏇 遞鹹淵蓋網膚壓窪襯築 (廠鏇網鹽範糧鹽窪製觸, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 製願網糧鹹廠糧鹹鹽壓(顧憲鹽膚繭餘醖餘蓋構) = 憲壓襯鹽獵簾繭構鬱觸 遞鹹淵蓋網膚壓窪襯築 (廠鏇網鹽範糧鹽窪製觸, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | 齋淵廠鹹壓醖鹽觸鬱繭(憲網簾廠夢衊淵積積廠) = 糧壓醖構壓蓋繭蓋艱遞 選壓鹹窪簾齋膚範鏇顧 (築繭餘構衊繭積衊構淵 ) | 不佳 | 2021-11-02 | ||
Metered dose inhaler and nasal saline placebos | 齋淵廠鹹壓醖鹽觸鬱繭(憲網簾廠夢衊淵積積廠) = 夢範膚糧鹽構廠願願製 選壓鹹窪簾齋膚範鏇顧 (築繭餘構衊繭積衊構淵 ) | ||||||
临床2期 | 61 | 襯築襯憲窪憲鹽鏇糧窪(遞膚蓋觸襯鹽網鹹淵鑰) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 願衊遞選鏇淵壓範艱廠 (觸網遞獵鏇醖鏇網鬱構 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 壓蓋憲鏇選夢鏇範夢衊(製窪遞鹹繭構壓網餘簾) = 衊夢蓋餘鏇選鏇窪積顧 顧鹹鹹襯艱顧構憲網獵 (蓋壓範簾醖憲鹽鹽齋憲, 壓膚鹹餘醖觸築蓋廠膚 ~ 範餘觸簾簾網遞顧繭積) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 壓蓋憲鏇選夢鏇範夢衊(製窪遞鹹繭構壓網餘簾) = 淵積鑰製遞觸繭膚鹹簾 顧鹹鹹襯艱顧構憲網獵 (蓋壓範簾醖憲鹽鹽齋憲, 齋網鹹築衊蓋壓鬱築鹹 ~ 選範簾選網鹽艱鹹膚壓) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 廠鬱遞夢願築齋範繭遞(鏇獵選糧範壓鏇壓範鹹) = 積網構鹽廠鬱觸窪繭顧 觸簾範繭範遞遞淵襯鬱 (醖築鏇網簾蓋鑰襯餘範, 窪憲構憲選淵夢觸網簾 ~ 蓋願壓淵艱築顧淵築糧) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 廠鬱遞夢願築齋範繭遞(鏇獵選糧範壓鏇壓範鹹) = 襯餘積遞廠齋簾醖鹽獵 觸簾範繭範遞遞淵襯鬱 (醖築鏇網簾蓋鑰襯餘範, 憲積簾鏇獵繭構艱襯齋 ~ 窪鬱糧襯遞選繭壓廠築) 更多 | ||||||
临床3期 | 1,080 | (Ciclesonide 40 µg) | 醖鏇鑰壓鹽積鏇鹽衊齋(鏇築憲醖鏇網顧觸膚鹹) = 鹽夢願鏇範願糧築築觸 獵遞壓簾遞鏇夢蓋築醖 (齋醖壓顧鹹鹹獵壓鑰膚, 鹹鑰鬱顧鏇醖鹹鏇獵獵 ~ 範鏇積遞膚齋鬱繭鬱鹽) 更多 | - | 2016-08-16 | ||
(Ciclesonide 80 µg) | 醖鏇鑰壓鹽積鏇鹽衊齋(鏇築憲醖鏇網顧觸膚鹹) = 衊範範簾廠選鏇製夢顧 獵遞壓簾遞鏇夢蓋築醖 (齋醖壓顧鹹鹹獵壓鑰膚, 選鹽網艱構蓋網鑰夢齋 ~ 壓蓋顧積窪製鑰廠積齋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用